CCassured’s Post

The landscape of personalized cancer therapies is constantly evolving. TIL therapies have garnered recent attention following the first #FDA approval in the class in March of this year. How might TIL therapies impact the landscape of #cancer treatment moving forward? In our latest blog, we explore the opportunities and challenges in leveraging TIL therapies. Learn more about commercial implications and strategies for advancing TIL therapies here: https://bit.ly/3Wx90QY Vivek Mittal, Ned Wydysh, Earl Gillespie, Matthew Chin, Meghan Lu

The #celltherapy landscape continues to evolve rapidly, and the launch of the first #TIL therapy only heightens the effort to bring these important therapeutic options to patients. In our latest blog, my colleagues discuss the opportunities and challenges facing developers. #CGT #healthadvances #ASCGT #oncology

Excited to announce that APPERTURE HEALTH will be presenting our latest research at #ISPOREurope! Join us at Poster EE184 on Monday, Nov 18, 2024 | 16:00 - 19:00 for a discussion on The European Pricing Landscape for Targeted Therapies in Advanced or Metastatic Non-Small Cell Lung Cancer! We look forward to meeting you and discussing our research. #HEOR #MarketAccess #Pricing #NSCLC #HealthcareResearch #LifeSciences #AmplifyingValue #AppertureInsights

📆 Save the Date: April 9-11, 2025 🌆 Salt Lake City, Utah 🌟 12th Annual Cholangiocarcinoma Foundation Conference 🌎 International Consensus on Research Priorities The upcoming Annual Conference is a unique opportunity for patients and caregivers to sit side-by-side with experts in the field and provide their voices in helping focus research priorities. It is an effort between CCF’s International Cholangiocarcinoma Research Network (ICRN) and the European Cooperation in Science and Technology (COST)-Action: BTC Precision Network, part of the European Network for the Study of Cholangiocarcinoma. 🤝 The initiative brings together patients, caregivers, advocates, oncologists, researchers, industry, young investigators, regulators, and other specialists worldwide to review scientific evidence, share insights, and reach a consensus, or full agreement, on the research focus going forward to optimize existing funding and attract new funding. 🔬 Developing research priorities is crucial, and it is vital that we have the voices of patients, caregivers, advocates, and the scientific community. We hope to see you all there! 📝 Sign up for updates here: https://lnkd.in/g2rZwqKU #CCFAC25 #SLC #CureCCA #oncologyresearch #rarecancer #younginvestigators #patientadvocacy #caregiversupport #CCAHope

Exciting news from the Oncology Outcomes (O2) team 📣 We are proud that several of our members are presenting #groundbreaking research 📊 at the upcoming ISPOR EU conference. Our work continues to push the boundaries in patient-centric cancer #research 🔬 In this post, we highlight a few of our posters: "Exploring the Development, Evaluation, and Impact of Researcher-Led Patient and Family Advisory Councils in Cancer Research": An insightful look at how advisory councils contribute to meaningful research #outcomes. "Barriers and Facilitators to the Recruitment of Diverse Populations into Patient Engagement Groups: A Scoping Review": Identifying key challenges and #opportunities for fostering #inclusivity. "Oncology Patient and Caregivers’ Perspectives on Value Assessment Frameworks: A Qualitative Study": Capturing first hand #insights on what brings #value to those directly affected by #cancer. Each piece represents our #commitment to ensuring research not only informs but deeply resonates with those it impacts 🙏🏼 If you are at ISPOR EU, come meet our team 👋🏼 and engage with us on how we can collectively reshape cancer research for the better 💫 #realworlddata #realworldevidence #rwd #rwe #patient #patients #engagement #data #analytics #advancedanalytics #outcomes #healthoutcomes #canceroutcomes #ISPOR #ISPOREU ISPOR—The Professional Society for Health Economics and Outcomes Research Christie Farrer Rogers Colleen Cuthbert

Join our webinar tomorrow!

📢 Check out the latest ONCOSCREEN blog and discover how ONCOSCREEN SOLUTIONS are bridging the gap between research and everyday life, revolutionizing early colorectal cancer diagnosis in Europe. Read more: shorturl.at/hrzYZ #HealthTech #CancerAwareness 🧬🔍

Registration is now open for our industry symposium 'Accelerating CF Research: Strategies for rapidly progressing your science to clinical impact', organised by Cystic Fibrosis Trust with support from LifeArc. Please register here to secure your place. https://lnkd.in/eDpmnCJH Places are limited and early registration is highly recommended to avoid disappointment. Date: Wednesday 5 June Time: 10.30am-1.30pm, including a networking lunch Location: Glasgow Science Centre, Pacific Quay, G51 1EA At this event you will find out more about: Uncovering funding opportunities: Learn how to secure funding for pre-clinical proof of principle studies. Accelerating your research: Find out how we can deliver research closer to patients and gain access to lived experience insights. Learn how to set up and deliver clinical trials through our Clinical Trials Accelerator Platform (CTAP). Diving into data-driven insights: Explore the power of data within the UK CF Registry to inform clinical trial design and support pharmacovigilance, pharmacoepidemiology and real-world evidence studies. Tapping into support: Discover how Cystic Fibrosis Trust, Medicines Discovery Catapult and LifeArc can work in partnership with you, providing you with resources, funding and support through the CF AMR Syndicate. We look forward to seeing you there! And please do share with anyone who might be interested.

Excited about the #EONS_SubcutaneousImmunotherapysymposium? We are! Don’t miss insightful sessions on SC immunotherapy, safe administration, & managing side effects. See you on Sep 15, 12:00 – 13:30 hrs CEST at Fira Barcelona Gran Via! Join the conversation with Lena Sharp, Guillermo De Velasco Oria de Rueda, Zoe O’Neil and Eva Muñoz Couselo, MD, PhD using hashtags #EONS17, #ESMO24 and #EONS_SubcutaneousImmunotherapy Event supported by Bristol Myers Squibb

Did you know there’s more on Vivli than just clinical trial data? Find out more about what's available in our repository of nearly 7,000 studies, and how you can access data that will take your research further: https://lnkd.in/es33eG_d